GRDX

GRDX is not a business you can underwrite on numbers — it is a serial reinvention. The entity was First Wave BioPharma, became Entero Therapeutics in May 2024, and on September 30, 2025 reverse-merged into Grid AI Corp./AMPX to become 'GridAI Technologies,' an AI-data-center energy-orchestration story. The MD&A concedes the flagship platform is 'currently in the development stage' with 'no revenue generated,' and the pipeline was only 'recently re-established' through consulting engagements. The FY2025 income statement bears this out brutally: $36.3K of revenue against a -$657K gross profit (gross margin -1,814%), a -$7.08M operating loss, and a -$209M accumulated deficit. This is a pre-revenue concept wrapped in a public shell, not an operating company.

The balance sheet makes it worse. Cash is $900K against operating cash burn of -$5.70M per year — under two months of runway. Management does not hide this: the very first risk factor states dependency on external funding 'raises a substantial doubt about our ability to continue as a going concern,' and warns it 'will require substantial additional financing.' With shares already up 30.1% year-over-year, the near-certain fix is dilutive equity issuance at a $27.3M market cap, directly eroding the 6.20M existing shareholders. The filing also flags 'significant board and management turnover during the fourth quarter of 2025' — governance instability layered on top of a solvency question.